

MUNICIPAL YEAR 2014/2015

MEETING TITLE AND DATE
Health and Wellbeing Board
11 December 2014

Report of: Dr Shahed Ahmad
Director of Public Health

Contact Officer:
Allison Duggal: 020 8379 2894
E mail: Allison.Duggal@enfield.gov.uk

Agenda - Part: 1	Item: 5
Subject: Pharmaceutical Needs Assessment	
Wards:All	
Cabinet Member consulted:	
Approved by:	

1. EXECUTIVE SUMMARY

- Enfield Health and Wellbeing Board (HWB) has a statutory duty to produce a Pharmaceutical Needs Assessment (PNA) by 1 April 2015
- The PNA is a statement of needs for pharmaceutical service provision within the HWB area.
- The PNA will be used by NHS England to determine applications from providers to provide pharmaceutical services. In addition, it will be used by CCGs and the local authority to consider services that may be provided from pharmaceutical service providers to reduce inequalities, improve access, and improve the health and wellbeing of the population
- The HWB have delegated the responsibility to oversee the production of the PNA to a Steering Group chaired by a Consultant in Public Health.

2. RECOMMENDATIONS

- The HWB is asked to note the points in this paper

3. BACKGROUND

Background

- Enfield Health and Wellbeing Board (HWB) has a statutory duty to produce a Pharmaceutical Needs Assessment (PNA) by 1 April 2015
- The PNA is a statement of needs for pharmaceutical service provision within the HWB area.
- Pharmaceutical services include the majority of services provided by community pharmacies, as well as dispensing providing from dispensing GP practices and appliance contractors
- The PNA will be used by NHS England to determine applications from providers to provide pharmaceutical services. In addition, it will be used by CCGs and the local authority to consider services that may be provided from pharmaceutical service providers to reduce inequalities, improve access, and improve the health and wellbeing of the population
- The HWB have delegated the responsibility to oversee the production of the PNA to a Steering Group
- Writing of the PNA has been outsourced to a specialist company, Soar Beyond, following a procurement earlier this year

Steering Group (SG)

- The SG is chaired by Allison Duggal, Consultant in Public Health
- The SG is made up of representatives from Enfield Council, Enfield Healthwatch, Middlesex Pharmaceutical group, NHS England and Enfield CCG
- Members of the SG have been chosen because of their local knowledge, representation, and experience in previous PNA productions
- The SG has met to discuss, plan and progress for the development of the PNA
- Terms of Reference for the SG have been agreed. The main role of the SG is to facilitate the production of the PNA, which is being led by the Chair
- In addition to the SG, a series of web and telephone meetings have been planned between the SG Chair and the project team in Soar Beyond

Draft PNA production

- The production of the Draft PNA includes the collation of pharmacy service provision (provided by NHS England), and public health data (provided by Enfield Council)
- A timeline for the production of the Draft PNA was agreed by the Steering Group
- The draft PNA has now been produced and, after discussions at the last Steering Group meeting, will be going out for wider consultation on the 1 December.

Consultation

- The 2013 Pharmaceutical Regulations, covering the PNA's production, include a requirement to consult for 60 days on the Draft PNA; this has been proposed by the SG to be conducted between 1st December 2014 and 31st January 2015.
- It is planned for the final PNA to be presented at the HWB meeting on 12th March 2015, following completion of the consultation and consideration of the responses
- The HWB will be asked to approve the final PNA for publication to meet our statutory obligations.

4. ALTERNATIVE OPTIONS CONSIDERED

Not applicable

5. REASONS FOR RECOMMENDATIONS

The pharmaceutical needs assessment needs to be consulted on for 60 days and will be brought to the WHB for final sign-off in March 2015 before publication.

6. COMMENTS OF THE DIRECTOR OF FINANCE, RESOURCES AND CUSTOMER SERVICES AND OTHER DEPARTMENTS

6.1 Financial Implications

There are no financial implications as a result of producing a Pharmaceutical Needs Assessment (PNA), however as a result of the PNA, should there be additional expenditure incurred to reduce inequalities, improve access, and improve the health and wellbeing of the population, this will have to be contained within the existing Public Health grant.

6.2 Legal Implications

Section 128A of the National Health Service Act 2006 requires every Health and Wellbeing Board to assess pharmaceutical need in its area, and publish a pharmaceutical needs assessment.

Regulation 5 of the National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013 ('the Regulations') requires each Health and Wellbeing Board to publish its Pharmaceutical Needs Assessment by 1 April 2015. The Regulations set out requirements for contents of the Assessment, consultation, and matters to be considered.

The matters set out in this report comply with the above requirements.

7. KEY RISKS

8. IMPACT ON PRIORITIES OF THE HEALTH AND WELLBEING STRATEGY

- 8.1** Ensuring the best start in life
- 8.2** Enabling people to be safe, independent and well and delivering high quality health and care services
- 8.3** Creating stronger, healthier communities
- 8.4** Reducing health inequalities – narrowing the gap in life expectancy
- 8.5** Promoting healthy lifestyles

The provision of good quality pharmaceutical services for the population of Enfield contributes to all of the priorities of the Health and Wellbeing Board.

9. EQUALITIES IMPACT IMPLICATIONS

There is an Equalities Impact Analysis (EqIA) in development for this needs assessment.

Background Papers

- Draft pharmaceutical needs assessment can be found via the link below:

www.enfield.gov.uk/pna_consultation